Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia

References

• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin -deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–8.
   PubMed Web of Science ®Google Scholar
• Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol(Oxf). 2005;63(5):594–8.
   PubMed Web of Science ®Google Scholar
• Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88(1):1–17.
   PubMed Web of Science ®Google Scholar
• Ciccone MM, Scicchitano P, Gesualdo M, Zito A, Carbonara R, Locorotondo M, et al. Serum osteoprotegerin and carotid intima-media thickness in acute/chronic coronary artery diseases. J Cardiovasc Med (Hagerstown). 2013;14(1):43–8.
   PubMed Web of Science ®Google Scholar
• Kim J, Song TJ, Yang SH, Lee OH, Nam HS, Kim YD, et al. Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis. Clin Biochem. 2013;46(12):1036–40.
   PubMed Web of Science ®Google Scholar
• Choe JY, Lee GH, Kim SK. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. J Rheumatol. 2011;38(3):485–91.
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111–5.
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D, et al. Uric Acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3–4):e71–8.
   Google Scholar
• Agabiti-Rosei E, Grassi G. Beyond gout: uric acid and cardiovascular diseases. Curr Med Res Opin. 2013;29(Suppl 3):33–9.
   PubMed Web of Science ®Google Scholar
• Meléndez-Ramírez G, Pérez-Méndez O, López-Osorio C, Kuri-Alfaro J, Espinola-Zavaleta N. Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. Endocr Res. 2012;37(1):1–6.
   PubMed Web of Science ®Google Scholar
• Yelken B, Caliskan Y, Gorgulu N, Altun I, Yilmaz A, Yazici H, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012;77(4):275–82.
   PubMed Web of Science ®Google Scholar
• Schumacher HR, Chen LX. Gout and other crystal-associated artheropathies. In Fauci AS, editors. Harrison's Rheumatology. New York: McGraw-Hill Medical; 2008:235–8.
   Google Scholar
• Xiang GD, Pu JH, Sun HL, Zhao LS. Alpha-lipoic Acid Improves Endothelial Dysfunction in Patients with Subclinical Hypothyroidism. Exp Clin Endocrinol Diabetes. 2010;118(9):625–9.
   PubMed Web of Science ®Google Scholar
• Xiang G, Xiang L, Xiang L, Wang H, Dong J. Change of plasma osteoprotegerin and its association with endothelial dysfunction before and after exercise in Hashimoto's thyroiditis with euthyroidism. Exp Clin Endocrinol Diabetes. 2012;120(9):529–34.
   PubMed Web of Science ®Google Scholar
• Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 2004;74(1):103–6.
   PubMed Web of Science ®Google Scholar
• McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009;12(1):35–46.
   PubMed Web of Science ®Google Scholar
• Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res. 2008;76(3):139–44.
   PubMed Web of Science ®Google Scholar
• Di Bartolo BA, Schoppet M, Mattar MZ, Rachner TD, Shanahan CM, Kavurma MM. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res. 2011;91(3):537–45.
   PubMed Web of Science ®Google Scholar
• Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006;26(9):2117–24.
   PubMed Web of Science ®Google Scholar
• Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21(10):1610–6.
   PubMed Web of Science ®Google Scholar
• Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 2004;50(1):277–90.
   PubMed Web of Science ®Google Scholar
• Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204(2):321–9.
   PubMed Web of Science ®Google Scholar
• Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J. 2012; 46(4):203–11.
   PubMed Web of Science ®Google Scholar
• Simão AN, Lozovoy MA, Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opin Ther Targets. 2012;16(12):1175–87.
   PubMed Web of Science ®Google Scholar
• Chuang SY, Chen JH, Yeh WT, Wu CC, Pan WH. Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Int J Cardiol. 2012;154(3):316–21.
   PubMed Web of Science ®Google Scholar
• Winnard D, Wright C, Jackson G, Gow P, Kerr A, McLachlan A, et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J. 2012;126(1368):53–64.
   PubMedGoogle Scholar
• Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction, a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168–75.
   PubMed Web of Science ®Google Scholar
• Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract. 2007;76(2):199–206.
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–42.
   PubMed Web of Science ®Google Scholar
• Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20(3):182–7.
   PubMed Web of Science ®Google Scholar
• Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148(1):131–9.
   PubMed Web of Science ®Google Scholar
• Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J. 1999;340(Pt 1):143–52.
   PubMed Web of Science ®Google Scholar
• Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008; 5(6):338–49.
   PubMedGoogle Scholar
• Nedeljkovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J. 2003;79(930):195–9.
   PubMed Web of Science ®Google Scholar
• George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508–16.
   PubMed Web of Science ®Google Scholar
• Aydin H, Deyneli O, Yavuz D, Yüksel M, Tarçin O, Yazici D, et al. Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. Minerva Endocrinol 2011;36(2):107–15.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimbürger O, et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol. 2009;22(6):774–82.
   PubMed Web of Science ®Google Scholar
• Zapolski T, Waciński P, Kondracki B, Rychta E, Buraczyńska MJ, Wysokiński A. Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiol Pol. 2011;69(4): 319–26.
   PubMed Web of Science ®Google Scholar
• Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond). 2005;108(3):237–43.
   PubMed Web of Science ®Google Scholar